The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28072531 |
120 |
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. |
Arena Pharmaceuticals |
| 28523115 |
59 |
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
Novartis Institutes For Biomedical Research |
| 28169162 |
86 |
Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
Askat |
| 15013022 |
46 |
Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected]. |
Roche Palo Alto |
| 27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
| 27484513 |
1 |
The therapeutic journey of pyridazinone. |
Jamia Hamdard |
| 28105284 |
55 |
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists. |
Ono Pharmaceutical |
| 26985320 |
89 |
Discovery of G Protein-Biased EP2 Receptor Agonists. |
Ono Pharmaceutical |
| 27133594 |
6 |
Piperidine derivatives as nonprostanoid IP receptor agonists 2. |
Toray Industries |
| 26996371 |
27 |
Piperidine derivatives as nonprostanoid IP receptor agonists. |
Toray Industries |
| 27055938 |
82 |
Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists. |
Ono Pharmaceutical |
| 26988801 |
55 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. |
Jagiellonian University Medical College |
| 25666818 |
95 |
Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat. |
Arena Pharmaceuticals |
| 26061158 |
136 |
A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques. |
Amgen |
| 24900877 |
107 |
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors. |
Merck Research Laboratories |
| 24279689 |
56 |
Prostanoid receptor EP2 as a therapeutic target. |
Emory University |
| 24021582 |
52 |
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. |
Novartis Institutes For Biomedical Research |
| 23582449 |
20 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor. |
Institute Of Organic Synthesis |
| 23466604 |
36 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds. |
Universit£ |
| 18359630 |
37 |
Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold. |
Merck Frosst Canada |
| 18291643 |
76 |
Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. |
Merck Frosst Centre For Therapeutic Research |
| 16931013 |
138 |
Comparison between two classes of selective EP(3) antagonists and their biological activities. |
Merck Frosst Centre For Therapeutic Research |
| 15935660 |
3 |
Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. |
Fujisawa Pharmaceutical |
| 15914004 |
34 |
Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
Fujisawa Pharmaceutical |
| 12643927 |
164 |
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. |
Merck Frosst Centre For Therapeutic Research |
| 21982795 |
81 |
Discovery of new orally active prostaglandin D2 receptor antagonists. |
Ono Pharmaceutical |
| 21958540 |
95 |
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis. |
Amira Pharmaceuticals |
| 21885288 |
109 |
Design and synthesis of new prostaglandin D2 receptor antagonists. |
Minase Research Institute |
| 21737285 |
138 |
Discovery of selective indole-based prostaglandin D2 receptor antagonist. |
Minase Research Institute |
| 21211969 |
42 |
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist. |
Amira Pharmaceuticals |
| 21208803 |
81 |
The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid. |
Merck Frosst Centre For Therapeutic Research |
| 21036609 |
38 |
Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore. |
Merck Frosst Centre For Therapeutic Research |
| 20471829 |
43 |
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. |
Merck Frosst Canada |
| 20303752 |
143 |
1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists. |
Decode Chemistry |
| 19836233 |
31 |
Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists. |
Decode Chemistry |
| 20163116 |
116 |
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. |
Merck Frosst Centre For Therapeutic Research |
| 19957930 |
126 |
Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that |
Decode Chemistry |
| 19608418 |
95 |
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis. |
Amira Pharmaceuticals |
| 19487124 |
39 |
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists. |
Glaxosmithkline |
| | 4 |
Molecular design of novel PGI2 agonists without PG skeleton. IV |
TBA |
| | 8 |
Molecular design of novel PGI2 agonists without PG skeleton. III |
TBA |
| | 11 |
Molecular design of novel PGI2 agonists without PG skeleton. II |
TBA |
| | 11 |
Molecular design of novel PGI2 agonists without PG skeleton. I |
TBA |
| 19332369 |
43 |
Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. |
Glaxosmithkline |
| 19307115 |
89 |
Discovery of potent and selective DP1 receptor antagonists in the azaindole series. |
Merck Frosst Centre For Therapeutic Research |
| 19188065 |
116 |
3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists. |
Decode Chemistry |
| 18701276 |
97 |
Highly functionalized 7-azaindoles as selective PPAR gamma modulators. |
Merck Research Laboratories |
| 17300164 |
62 |
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). |
Merck Frosst Canada |
| 16837197 |
14 |
Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. |
Fujisawa Pharmaceutical |
| 16529930 |
96 |
Identification of an indole series of prostaglandin D2 receptor antagonists. |
Merck Frosst Canada |
| 16078846 |
40 |
Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives. |
Toray Industries |
| 15935659 |
17 |
Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
Fujisawa Pharmaceutical |
| 15857112 |
55 |
Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
Fujisawa Pharmaceutical |
| 14643308 |
2 |
A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic. |
Fujisawa Pharmaceutical |
| 14552786 |
88 |
Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
| 12182865 |
88 |
Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
| 11708917 |
33 |
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. |
Procter & Gamble Pharmaceuticals |
| 11454474 |
84 |
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability. |
Minase Research Institute |
| 11454473 |
119 |
Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity. |
Minase Research Institute |
| 11454472 |
107 |
Design and synthesis of a highly selective EP2-receptor agonist. |
Minase Research Institute |
| 11266183 |
32 |
Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. |
Merck Frosst Canada |
| 11133092 |
2 |
A novel pyridazinone derivative as a nonprostanoid PGI2 agonist. |
Fujisawa Pharmaceutical |
| 10715159 |
112 |
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. |
Procter And Gamble Pharmaceuticals |
| 10509919 |
103 |
New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
| 9357516 |
94 |
Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists. |
Shionogi |
| 1370696 |
6 |
Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
Search and Browse
